A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders
Identifieur interne : 005430 ( Main/Merge ); précédent : 005429; suivant : 005431A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders
Auteurs : Steven J. Frucht [États-Unis] ; Yvette Bordelon [États-Unis] ; William H. Houghton [États-Unis] ; Dayton Reardan [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol-responsive movement disorders in an open-label. dose-titration, add-on, 8-week trial. All five patients (one with severe alcohol-responsive posthypoxic myoclonus. two with e-sarcoglycan-linked myoclonus-dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose-dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001D42
- to stream PascalFrancis, to step Curation: 000F79
- to stream PascalFrancis, to step Checkpoint: 001F52
Links to Exploration step
Pascal:06-0000276Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Orphan Medical, Inc</s1><s2>Minnetonka, Minnesota</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Orphan Medical, Inc</s1><s2>Minnetonka, Minnesota</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0000276</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 06-0000276 INIST</idno><idno type="RBID">Pascal:06-0000276</idno><idno type="wicri:Area/PascalFrancis/Corpus">001D42</idno><idno type="wicri:Area/PascalFrancis/Curation">000F79</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001F52</idno><idno type="wicri:doubleKey">0885-3185:2005:Frucht S:a:pilot:tolerability</idno><idno type="wicri:Area/Main/Merge">005430</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders</title><author><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Columbia University Medical Center</s1><s2>New York, New York</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Orphan Medical, Inc</s1><s2>Minnetonka, Minnesota</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Orphan Medical, Inc</s1><s2>Minnetonka, Minnesota</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Minnesota</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ethanol</term><term>Myoclonus</term><term>Nervous system diseases</term><term>Sodium oxybate</term><term>Tremor</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Myoclonie</term><term>Tremblement</term><term>Oxybate sodium</term><term>Ethanol</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sodium oxybate is currently approved in the United States exclusively for the treatment of cataplexy in narcoleptic patients. In a prior article published in this journal, we reported a patient with severe posthypoxic myoclonus whose myoclonus improved with ethanol and also with treatment with sodium oxybate. We extend this preliminary observation to five other patients with ethanol-responsive movement disorders in an open-label. dose-titration, add-on, 8-week trial. All five patients (one with severe alcohol-responsive posthypoxic myoclonus. two with e-sarcoglycan-linked myoclonus-dystonia, and two with essential tremor) experienced improvement from baseline of 50% or greater as measured by blinded videotape review. Tolerability was satisfactory, with dose-dependent sedation as the most common side effect. Further studies of this drug in hyperkinetic movement disorders are warranted.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Minnesota</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Frucht, Steven J" sort="Frucht, Steven J" uniqKey="Frucht S" first="Steven J." last="Frucht">Steven J. Frucht</name></region><name sortKey="Bordelon, Yvette" sort="Bordelon, Yvette" uniqKey="Bordelon Y" first="Yvette" last="Bordelon">Yvette Bordelon</name><name sortKey="Houghton, William H" sort="Houghton, William H" uniqKey="Houghton W" first="William H." last="Houghton">William H. Houghton</name><name sortKey="Reardan, Dayton" sort="Reardan, Dayton" uniqKey="Reardan D" first="Dayton" last="Reardan">Dayton Reardan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005430 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005430 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:06-0000276
|texte= A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders
}}
| This area was generated with Dilib version V0.6.23. |  |